IL105344A - Pharmaceutical compositions targeted against CD33 related surface antigens - Google Patents

Pharmaceutical compositions targeted against CD33 related surface antigens

Info

Publication number
IL105344A
IL105344A IL10534493A IL10534493A IL105344A IL 105344 A IL105344 A IL 105344A IL 10534493 A IL10534493 A IL 10534493A IL 10534493 A IL10534493 A IL 10534493A IL 105344 A IL105344 A IL 105344A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
surface antigens
targeted against
related surface
compositions targeted
Prior art date
Application number
IL10534493A
Other languages
English (en)
Other versions
IL105344A0 (en
Original Assignee
Res Developments Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Developments Foundation filed Critical Res Developments Foundation
Publication of IL105344A0 publication Critical patent/IL105344A0/xx
Publication of IL105344A publication Critical patent/IL105344A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL10534493A 1992-04-10 1993-04-08 Pharmaceutical compositions targeted against CD33 related surface antigens IL105344A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86669392A 1992-04-10 1992-04-10

Publications (2)

Publication Number Publication Date
IL105344A0 IL105344A0 (en) 1993-08-18
IL105344A true IL105344A (en) 2000-06-29

Family

ID=25348185

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10534493A IL105344A (en) 1992-04-10 1993-04-08 Pharmaceutical compositions targeted against CD33 related surface antigens

Country Status (13)

Country Link
EP (2) EP1656950A1 (ru)
JP (1) JP3949158B2 (ru)
KR (1) KR950700760A (ru)
CN (1) CN1056084C (ru)
AU (1) AU675226B2 (ru)
CA (1) CA2133838C (ru)
FI (1) FI944730A (ru)
IL (1) IL105344A (ru)
NO (1) NO314686B1 (ru)
NZ (1) NZ252799A (ru)
RU (1) RU2127122C1 (ru)
WO (1) WO1993020848A1 (ru)
ZA (1) ZA932523B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599505B1 (en) 1992-04-10 2003-07-29 Research Development Foundation Immunotoxins directed against CD33 related surface antigens
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
DK2116259T3 (da) * 2001-05-24 2012-05-21 Zymogenetics Inc TACI-immunoglobulinfusionsproteiner
TW200726776A (en) * 2005-07-29 2007-07-16 Friedrich Alexander University Of Erlangen Nuremberg CD33-specific single-chain immunotoxin and methods of use
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
WO2016201389A2 (en) 2015-06-12 2016-12-15 Alector Llc Anti-cd33 antibodies and methods of use thereof
US11136390B2 (en) 2015-06-12 2021-10-05 Alector Llc Anti-CD33 antibodies and methods of use thereof
BR112019023789A2 (pt) 2017-08-03 2020-07-28 Alector Llc anticorpos anti-cd33 e métodos de uso dos mesmos
AU2019331018A1 (en) 2018-08-31 2021-03-11 Alector Llc Anti-cd33 antibodies and methods of use thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
CA2072017A1 (en) * 1989-12-14 1991-06-15 David A. Scheinberg Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof

Also Published As

Publication number Publication date
RU2127122C1 (ru) 1999-03-10
CA2133838A1 (en) 1993-10-28
JPH08501059A (ja) 1996-02-06
NO943776L (no) 1994-11-25
FI944730A0 (fi) 1994-10-07
NO314686B1 (no) 2003-05-05
EP0634938A1 (en) 1995-01-25
KR100291377B1 (ru) 2001-09-17
WO1993020848A1 (en) 1993-10-28
JP3949158B2 (ja) 2007-07-25
FI944730A (fi) 1994-10-07
NZ252799A (en) 1996-10-28
AU675226B2 (en) 1997-01-30
CN1078401A (zh) 1993-11-17
NO943776D0 (no) 1994-10-07
KR950700760A (ko) 1995-02-20
CN1056084C (zh) 2000-09-06
AU4280193A (en) 1993-11-18
EP1656950A1 (en) 2006-05-17
IL105344A0 (en) 1993-08-18
ZA932523B (en) 1994-10-08
EP0634938A4 (en) 1998-06-03
CA2133838C (en) 2003-07-29

Similar Documents

Publication Publication Date Title
ZA938825B (en) Pharmaceutical compositions
GB9308014D0 (en) Pharmaceutical compositions
GB9319500D0 (en) Pharmaceutical composition
HUT66864A (en) Pharmaceutical compositions
IL105344A (en) Pharmaceutical compositions targeted against CD33 related surface antigens
GB2272375B (en) Pharmaceutical composition
GB9209874D0 (en) Pharmaceutical compositions
ZA937592B (en) Pharmaceutical composition
ZA94155B (en) Pharmaceutical composition
ZA935078B (en) Pharmaceutical composition
GB9226377D0 (en) Pharmaceutical compositions
ZA935931B (en) Pharmaceutical composition
ZA924061B (en) Pharmaceutical composition
GB9211276D0 (en) Pharmaceutical compositions
GB9224339D0 (en) Surface following device
ZA931984B (en) Pharmaceutical composition
GB9211903D0 (en) Pharmaceutical composition
GB9225170D0 (en) Pharmaceutical composition
ZA931863B (en) Pharmaceutical composition
GB9225159D0 (en) Pharmaceutical composition
GB9216600D0 (en) Pharmaceutical composition
GB9216596D0 (en) Pharmaceutical composition
GB9213042D0 (en) Pharmaceutical composition
GB9206046D0 (en) Pharmaceutical composition
GB9210335D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees